

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Dr. Sophie Lucas

Application No.: Not yet assigned

Group Art Unit: Not yet assigned

Filed: Concurrently herewith

Examiner: Not yet assigned

For: ISOLATED NUCLEIC ACID MOLECULES
CODING FOR TUMOR REJECTION
ANTIGEN PRECURSORS OF MEMBERS OF
THE MAGE-C AND MAGE-B FAMILIES
AND USES THEREOF

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Prior to examination, please amend the application as follows:

IN THE SPECIFICATION

Please delete the paragraph on page 1, lines 6-13, and insert therefore

-- This application is a divisional application of Serial No. 09/501,104 filed February 9, 2000 which is a CIP of Application No. 09/468,433 now abandoned which is a CIP of 09/066,281 filed April 24, 1998, which is a CIP of Application No. 08/845,528 filed April 25, 1997 now U.S. Patent No. 6,027,924 all of which are incorporated herein in their entirety by reference.

IN THE CLAIMS

Please cancel claims 1-27, 29-30 and 32-33 without prejudice.

10085406-070102

REMARKS


Applicants have cancelled claims 1-27, 29-30 and 32-33 without prejudice and expressly reserving the right to prosecute the subject matter of these cancelled claims in one or more subsequent applications.

This application is a divisional of Application No. 09/501,104 filed February 9, 2000 (the parent application). The parent application was subjected to a restriction requirement in an Office Action mailed May 8, 2001. Applicants hereby elect the Group XIX, i.e., claim 31 with traverse. Applicants respectfully request that claim 28, currently assigned to Group I be examined concurrently with claim 31. Both claims relate to the use of identical primers i.e. an oblongonucleotide having a sequence set forth by nucleotides 175-195 of SEQ ID NO:21 and an oblongonucleotide having a nucleotide sequence that is complementary to nucleotides 711-731 of SEQ ID NO:1 in polymerase chain reactions. A search of these two claims is sufficiently overlapping to warrant their concurrent examination in the interest of compact prosecution.

Entry of this amendment is earnestly requested.

Dated: March 1, 2002

Respectfully submitted,

By 
Mary Ann Schofield
Registration No.: 36,669

FULBRIGHT & JAWORSKI L.L.P.
Market Square
801 Pennsylvania Avenue, N.W.
Washington, DC 20004-2615
(202) 662-0200
Attorneys for Applicant

**CLEAN COPY OF ADDITION TO
THE SPECIFICATION**

**ISOLATED NUCLEIC ACID MOLECULES CODING FOR TUMOR
REJECTION ANTIGEN PRECURSORS OF MEMBERS OF THE
MAGE-C AND MAGE-B FAMILIES AND USES THEREOF**

- - This application is a divisional application of Serial No. 09/501,104 filed February 9, 2000 which is a CIP of Application No. 09/468,433, now abandoned, which is a CIP of Application No. 09/066,281 filed April 24, 1998, which is a CIP of Application No. 08/845,528 filed April 25, 1997 now U.S. Patent No. 6,027,924. - -